Seattle Genetics leader Clay Siegall Leads steps into finding the Cure for Cancer

Just like Silicon Valley is reputable for its cell phone, electronic and computer research, Seattle is the present cancer research center. Seattle has lately become a medical drug research hub where scientists are uniting to create the friendliest working environment. Good climate and plenty of nearby natural resources favor scientific research.

Clay Siegall’s contributions towards cancer treatment

Clay Siegall is one of the most experienced Seattle therapeutic drug and cancer research developers. He is driven by the motivation to discover cures for the many diseases that are destroying savings accounts and depleting family and company insurance funds. At the peak of his efforts to find corrective measures for cancer, Dr. Clay has shown commitment to helping all medical development aspects.

Beginning his education at the Maryland Zoology University, Dr. Clay later attained his Ph.D. from the University of George Washington. He went on to serve at the National Cancer Institute as well as the Bristol Meyers Squibb Pharmaceutical Research Institute.

He later founded his company, the Seattle Genetics where he serves as the enterprise research board director. Besides, Seattle Genetics, Dr. Clay also serves as the board director of Alder Biopharmaceuticals, Fred Hutchinson Cancer Research Business Alliance, and the American Biomedical Association.

Dr. Clay established Seattle Genetics on scientific innovation foundation, passion for helping patients as well as drug development practices. At Seattle Genetics, Dr. Clay has continuously been developing the range of products to cure cancer and other autoimmune diseases.

He has advanced antibody technology to create a unique type of antibody drugs that selectively destroys cancerous body cells. He has overseen his company’s leadership, a position that has enabled him to develop ADCs (antibody-drug conjugates) as well as the first ever brentuximab vedotin product. In partnership with the Takeda Pharmaceutical Company, Seattle Genetics has diversified into ADCs pipeline proprietary for cancer treatment.

Very often, the current cancer treatments have been too destructive and invasive. Most cancer treatments have often reduced the level of cancer cells in the body but left the human body too weak. Cancer continues to plague the society, leaving the kinds of Clay Siegall and Seattle Generics in desperate need to find cures.

Leave a Reply

Your email address will not be published. Required fields are marked *

*
*
Website